Skip to entry

Tirzepatide doses and indications, as labeled

GLP1Meds.org editorial team · Published November 18, 2026 · Last reviewed November 18, 2026

Tirzepatide activates GIP receptors and GLP-1 receptors. That dual activity is why it is a mistake to call Zepbound “a semaglutide.” The doses, the brands, and the trial that anchors the weight-loss claim are different. This entry follows the Zepbound prescribing information revised in the 2026 label PDF reviewed for this page, and the Mounjaro DailyMed record. It does not convert one into the other. Dated self-pay figures, where a manufacturer page stated them, are on a consumer cost guide. A separate price-check site, cheapestglp1withoutinsurance.com, tracks cash offers that this monograph will not try to keep live inside a dose table.

Zepbound indications

Zepbound is indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight and at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. FDA’s announcement of the sleep-apnea approval described two randomized trials in adults with obesity and without type 2 diabetes, one in people using positive airway pressure and one in people not using it, with 10 or 15 mg or placebo for 52 weeks, and a primary measure of change in the apnea-hypopnea index. The agency noted that the AHI improvement is likely related to weight reduction. Drugs@FDA application 217806 is the Zepbound application.

Limitations of use: Zepbound contains tirzepatide, and coadministration with other tirzepatide-containing products or any GLP-1 receptor agonist is not recommended. It is not described as a pediatric weight-loss drug.

Zepbound dose escalation

The starting dose for all indications is 2.5 mg injected subcutaneously once weekly for four weeks. The label says the 2.5 mg dose is for initiation and is not approved as maintenance. After four weeks the dose increases to 5 mg once weekly. Further increases are in 2.5 mg steps, after at least four weeks on the current dose. The purpose of that schedule, the label says, is to reduce gastrointestinal adverse reactions. If a maintenance dose is not tolerated, consider a lower maintenance dose.

Maintenance for weight reduction and long-term maintenance is 5 mg, 10 mg, or 15 mg once weekly. Maintenance for obstructive sleep apnea is 10 mg or 15 mg once weekly. The maximum for all indications is 15 mg once weekly.

A missed dose is taken as soon as possible within four days (96 hours). If more than four days have passed, skip it and take the next dose on the usual day. Do not double. Presentations include single-dose pens, single-dose vials, and a KwikPen. The label says never to share a KwikPen between patients, even if the needle is changed. Injection supplies for vials and KwikPens are not the same, and the medication guide tells patients which device they were prescribed. Administration can be in the abdomen or thigh, or another person can inject the back of the upper arm, with sites rotated. The dose can be taken any time of day, with or without meals.

What SURMOUNT-1 reported

SURMOUNT-1 assigned 2,539 adults with BMI of 30 or more, or 27 or more plus at least one weight-related complication, excluding diabetes, to tirzepatide 5, 10, or 15 mg or placebo once weekly for 72 weeks, including 20 weeks of escalation, plus lifestyle intervention aimed at a 500-calorie deficit and at least 150 minutes of activity a week. Mean baseline weight was 104.8 kg and mean BMI was 38.0. Using the treatment-regimen estimand, which counts effects regardless of discontinuation, mean weight change at week 72 was −15.0 percent with 5 mg, −19.5 percent with 10 mg, −20.9 percent with 15 mg, and −3.1 percent with placebo. At least 5 percent loss occurred in 85, 89, and 91 percent of the tirzepatide groups versus 35 percent with placebo. At least 20 percent loss occurred in 50 percent and 57 percent of the 10 mg and 15 mg groups versus 3 percent with placebo. The most common adverse events were gastrointestinal, mostly mild or moderate, and mostly during escalation. Adverse events led to discontinuation in 4.3, 7.1, and 6.2 percent of the 5, 10, and 15 mg groups and 2.6 percent with placebo.

The Zepbound label’s safety pool of two placebo-controlled weight trials, which is broader than SURMOUNT-1 alone, reports permanent discontinuation for adverse reactions in 4.8, 6.3, and 6.7 percent at 5, 10, and 15 mg versus 3.4 percent on placebo, mostly early gastrointestinal events. Reactions reported in at least 5 percent of treated patients include nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity, burping, hair loss, and gastroesophageal reflux. The label states that trial rates should not be compared directly with rates from another drug’s trials. Do not set these percentages next to Wegovy’s and declare a winner. The semaglutide entry has those other figures in their own trial context.

Boxed warning and other warnings

Zepbound’s boxed warning mirrors the GLP-1 class warning: thyroid C-cell tumors in rats, unknown human relevance, contraindication in personal or family history of medullary thyroid carcinoma and in MEN 2, and counseling about thyroid-tumor symptoms. The label also warns about severe gastrointestinal adverse reactions, acute kidney injury from dehydration related to gastrointestinal losses, gallbladder disease, pancreatitis including fatal cases, hypersensitivity, diabetic retinopathy complications in patients with type 2 diabetes, and pulmonary aspiration during general anesthesia or deep sedation. Pregnancy: the drug may cause fetal harm, and the label says to discontinue Zepbound when pregnancy is recognized. Hypoglycemia risk increases with insulin or an insulin secretagogue. Patients with type 2 diabetes are monitored for glucose.

None of those paragraphs is a reason to start at 15 mg because SURMOUNT-1’s largest mean was at 15 mg. The 15 mg arm got there through escalation, and discontinuation was not zero.

Mounjaro

Mounjaro is tirzepatide indicated for glycemic control in adults and in pediatric patients 10 years and older with type 2 diabetes, as an adjunct to diet and exercise. The DailyMed record reviewed for this entry also lists reduction of major adverse cardiovascular events in adults with type 2 diabetes at high risk. The starting dose is 2.5 mg subcutaneously once weekly. If more glycemic control is needed, the dose increases in 2.5 mg steps after at least four weeks. The adult maximum on that record is 15 mg weekly. The pediatric maximum is 10 mg weekly. Administration is once weekly, any time of day, with or without meals, in the abdomen or thigh, or by another person in the back of the upper arm.

Mounjaro’s diabetes schedule can look numerically similar to Zepbound’s. The indications and the populations are not the same, and the labels say not to combine tirzepatide products. A person who is prescribed Mounjaro for diabetes and also offered Zepbound for weight is being offered two products the limitation of use tells clinicians not to stack. The prescriber has to choose a plan, not a pair of memberships.

How to read a “tirzepatide” vial that is not one of these brands

A compounded tirzepatide vial is not Zepbound and not Mounjaro. It has not been through FDA approval of that finished product. FDA has warned about compounded GLP-1 dosing that exceeds labeled schedules and about adverse events from measurement errors. The oral and compounded entry collects those warnings. If the container does not match a Zepbound or Mounjaro presentation in the medication guide, do not “convert” the milligrams using this page. Ask the dispensing pharmacist what was compounded and ask the prescriber why an approved presentation was not used.

Label and trial list

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s041lbl.pdf
  2. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  3. https://pubmed.ncbi.nlm.nih.gov/35658024/
  4. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
  5. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806
  6. https://cheapestglp1withoutinsurance.com/
  7. https://glp1.here/guides/cost-and-first-weeks